Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 5.97M | 5.26M | 5.11M | 6.24M | 6.14M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 26.23M | 25.81M | 24.44M | 21.97M | 17.52M |
Operating Income | -26.23M | -25.81M | -24.44M | -21.97M | -17.52M |
Income Before Tax | -22.97M | -22.24M | -20.18M | -17.49M | -13.31M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -22.97M | -22.24M | -20.18M | -17.49M | -13.31M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -22.97M | -22.24M | -20.18M | -17.49M | -13.31M |
EBIT | -26.23M | -25.81M | -24.44M | -21.97M | -17.52M |
EBITDA | -26.22M | -25.80M | -24.43M | -21.96M | -17.51M |
EPS Basic | -0.89 | -0.86 | -0.78 | -0.68 | -0.55 |
Normalized Basic EPS | -0.56 | -0.72 | -0.49 | -0.42 | -0.35 |
EPS Diluted | -0.89 | -0.86 | -0.78 | -0.68 | -0.55 |
Normalized Diluted EPS | -0.56 | -0.72 | -0.49 | -0.42 | -0.35 |
Average Basic Shares Outstanding | 25.69M | 25.80M | 25.77M | 25.72M | 24.08M |
Average Diluted Shares Outstanding | 25.69M | 25.80M | 25.77M | 25.72M | 24.08M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |